Media Center

PAGE:   1 2 3 4 5 6 7 8 9

Sustaining our fight against TB

March 24, 2014

An interview with the Sandoz Global TB Team

Sandoz continues extensive Tuberculosis program

March 24, 2014

Fighting Tuberculosis (TB) is a key Corporate Responsibility initiative for Sandoz.

Fighting TB is more than making medicines

March 24, 2014

An interview with the Sandoz Global TB Team

Tuberculosis remains a global health challenge; Sandoz continues commitment to fighting the disease

March 21, 2014

Despite great progress made in the fight to eradicate Tuberculosis (TB), the disease remains a global killer and disproportionately affects the world’s poor. Sandoz, a leading provider of high-quality, affordable generic medicines, has the opportunity to significantly contribute to the fight against TB.

Sandoz is a leader in the fight against TB

March 20, 2014

Our TB commitment: in graphic form.

Sandoz expands Tuberculosis activities in Africa

March 19, 2014

The Sandoz Tuberculosis (TB) program is increasing its reach in Africa. Sandoz is expanding its Tuberculosis portfolio as well as its Corporate Responsibility initiatives to support positive health outcomes for more patients and ultimately, contribute towards the eradication of the disease.

Sandoz participates in development project: “Quality Assured Essential Medicines for Ghana”

March 14, 2014

Sandoz 1 A Pharma is pleased to participate in the develoPPP.de (DPP) project “Quality Assured Essential Medicines for Ghana,” a three-year development partnership aimed at increasing access to high-quality, affordable medicines for patients in Ghana.

Sandoz recognizes International Women’s Day, highlighting importance of healthcare access for women globally

March 07, 2014

Today Sandoz recognizes International Women’s Day (IWD), a globally-recognized day which celebrates the economic, social and cultural contributions made by women.

Sandoz publishes 2013 Diversity & Inclusion Annual Report

February 26, 2014

The D&I Annual Report provides an excellent overview of what Sandoz Diversity & Inclusion is all about and how our commitment to inclusion supports our business objectives.

Sandoz partners with WHO-CC to bring pharmacovigilance training to Ghana

Holzkirchen, Germany, February 24, 2014

Sandoz in Ghana recently partnered with the World Health Organization Collaboration Centre (WHO-CC) for Advocacy and Training in Pharmacovigilance to provide Ghanaian pharmacists with advanced training.

Nick Haggar comments on Sandoz in Africa

Holzkirchen, Germany, February 24, 2014

Nick Haggar comments on Sandoz in Africa

Sandoz opens office in Accra, Ghana

Holzkirchen, Germany, February 24, 2014

Sandoz officially opened its representative office in Accra, Ghana on January 23, 2014.

Sandoz hosts first-of-its-kind conference for generics in organ transplantation

February 17, 2014

Sandoz brought together 120 representatives of the European transplant community to cover topics such as engineering organs from stem cells and the use of generics in transplants.

Lek, a Sandoz company, recognized for its work-life integration efforts

December 27, 2013

The non-governmental organization Ekvilib Institute recently reconfirmed a full Family Friendly Company certificate for Lek, a Sandoz company. The certificate confirms Sandoz’s commitment to establishing a family friendly work environment, contributing to associate satisfaction and loyalty.

Sandoz US receives DGLCC Community Ally Award

December 20, 2013

The Sandoz Broomfield, Colorado site was honored with the Corporate Community Ally Award from the Denver Gay and Lesbian Chamber of Commerce at the 17th Annual Business Awards dinner on November 21.

Living with thyroid disease

June 21, 2013

Thyroid disease affects people all over the world. For example, about 3% of adults in the United States have a thyroid condition. See how thyroid disease has affected two patients in Japan and how they treat their disease to live a normal life.

Sandoz recognizes associates with D&I awards

June 13, 2013

We have another short news clip to put on our external channels – the Brazil D&I video.

Living with chronic pain

June 13, 2013

There are about 15 million people in Germany who suffer from chronic pain. 600,000 of those people require pain therapy. See how a former handy man with chronic pain manages to live a normal, active life.

Sandoz expands sterile penicillin production at Kundl site

June 10, 2013

Sandoz’s Kundl, Austria production site is the last remaining fully integrated penicillin producer in the western world. Hear about how we are investing in Kundl to increase annual capacity to more than 150 million vials in this short video.

Sandoz moves towards larger presence in Japan

June 06, 2013

How prevalent are generic medicines in Japan? What is Sandoz doing to increase its presence in the fast-growing Japanese market? Find out in this video featuring Jeff George, Sandoz Global.

Sandoz associates in Russia continue the spirit of Novartis Community Partnership Day

June 03, 2013

Sandoz associates in Russia continue the spirit of Novartis Community Partnership Day

Sandoz study highlights wellness management as key factor for growth in Spain (video)

May 28, 2013

Sandoz Spain commissioned an analysis of data from 3,300 pharmacies in Spain and found that a key factor for growth, despite the economic downturn in the country, is transforming the business concept to that of health and wellness management. Those pharmacies that devoted more time to consulting with customers on all aspects of health saw more growth than those who did not.

Regional BioCamp 2013 – Young scientists get a firsthand glimpse of the world of pharmacy (video)

Ljublijana, May 25, 2013

In alignment with Sandoz’s mission to increase patient access to high-quality medicines, the theme of the BioCamp was Contemporary Technologies for Affordable Therapies. Lectures, discussions and case studies centered on this theme.

Sandoz Austria celebrates Community Partnership Day 2013 (video)

May 14, 2013

Each year, Sandoz associates around the world give back to their communities by participating in Novartis Community Partnership Day

Sandoz launches diltiazem HCL ER capsules, USP, a generic version of TIAZAC®

Princeton, New Jersey, April 17, 2013

Sandoz today announced the US launch of diltiazem HCL ER capsules, USP, a generic version of Forest Labs’ TIAZAC®.

Sandoz in Spain wins “Best Initiatives of the Year” award

Madrid, Spain, March 11, 2013

Second year in a row Sandoz in Spain has been recognized by Correo Farmacéutico

Sandoz’s Vojmir Urlep in Slovenia wins business award

Ljubljana, Slovenia, March 05, 2013

On March 5, 2013, the Chamber of Commerce and Industry of Slovenia (CCIS) named Vojmir Urlep as one of the 8 winners of awards for outstanding business achievement.

Sandoz calls for US industry collaboration to ensure patient access to critical biologic medicines

February 25, 2013

Sandoz has issued a call to action to the US generics industry and other healthcare stakeholders, urging companies to join forces and seize the opportunity to drive patient access to affordable, high-quality biologics, or biosimilars.

Education and outreach increasing community’s access to medicines in Brazil

February 14, 2013

Associates from a cross-section of Sandoz Brazil are participating in the “Friends of Health” project in Cambé, a low income community in Brazil’s southern region

Sandoz strengthens US portfolio with acquisition of four generic products from Watson/Actavis

Princeton, New Jersey, October 16, 2012

Sandoz today announced that it will acquire four generic products from Watson/Actavis pursuant to the terms of definitive agreements between the parties, subject to Watson completing its planned acquisition of the Actavis group of companies.

Sandoz Biopharmaceuticals Opens New Cellular and Molecular Biology Laboratory in Mengeš

October 04, 2012

New investment will strengthen Sandoz Slovenia‘s role as an integral part of the company’s biosimilars development and production network.

Manager of the Year 2012 is Vojmir Urlep

Portorož, Slovenija, September 28, 2012

The management board of the Managers Association selected Vojmir Urlep, President of the Board of Management of Lek, a Sandoz company, as Manager of the Year 2012. Recognition will be awarded to him at the Management Congress on Thursday, 27 September, in Portorož.

Sandoz supports Zambian government in increasing access to high-quality, affordable medicines through Health Shops

Holzkirchen, Germany, August 24, 2012

On August 20, Sandoz and its subsidiary 1A Pharma announced its support for an innovative initiative by the Zambian government. Called Health Shops, this initiative will allow Sandoz to supply its high-quality, affordable medicines to independently owned and operated rural stores, which are the only healthcare providers in the rural communities of the country. In addition, Sandoz will work with these Health Shops to support quality standards in their shops.

Alabama Supreme Court Rules in Favor of Sandoz in Medicaid Pricing Case

Princeton, NJ, July 13, 2012

Alabama Supreme Court rules in favor of Sandoz overturning the earlier $78.4 million jury verdict. Sandoz pleased by ruling as the Company reported true and accurate prices.

Sandoz launches voriconazole injection, the first generic version of Vfend®

Princeton, New Jersey, May 30, 2012

Sandoz today announced the introduction of voriconazole injection, the first generic version of Pfizer’s Vfend®, in the US.

Sandoz K.K. announces co-promotion of Somatropin BS S.C. Injection 5mg/10mg [Sandoz] with Nipro Pharma Corporation in Japan

May 18, 2012

Sandoz K.K. today announced that it has entered an agreement with Nipro Pharma Corporation to co-promote Somatropin BS S.C. Injection 5mg/10mg [Sandoz] in Japan.

Sandoz launches generic Lipitor® across EU countries

Holzkirchen, Germany, May 14, 2012

Sandoz has launched atorvastatin film-coated tablets across countries of the European Union (EU), including in Belgium, Denmark, France, Germany (through its affiliate 1A Pharma GmbH), Ireland, Italy, the Netherlands and the United Kingdom, upon expiry of respective supplementary protection certificates (SPCs).

Community Partnership Day

April 26, 2012

1800 Sandoz associates join a Novartis global team of more than 25,000 to volunteer for local causes in Community Partnership Day.

Sandoz completes US offering of generic Lovenox® line with launch of enoxaparin sodium injection, USP vials

Princeton, New Jersey, April 25, 2012

Sandoz today announced the introduction of enoxaparin sodium injection, USP 3 mL vials, a generic version of Sanofi’s Lovenox® Injection Multiple-Dose Vials, in the US.

Sandoz enters local Cameroon production partnership to increase access to quality medicines in Sub-Saharan Africa

Yaoundé, Cameroon, April 23, 2012

Sandoz is pleased to announce that its German affiliate, 1A Pharma GmbH (1A Pharma), has signed an important partnership agreement with Cinpharm S.A. (Cinpharm), a Cameroon-owned and operated generic pharmaceuticals manufacturing company for the production of high-quality medicines for the Sub-Saharan African region.

First Barmer GEK Tender Awarded

Holzkirchen, March 07, 2012

Sandoz group clearly ahead with over a third of contracts won.

Atorvastatin HEXAL®: Significant relief before patent expiration

Holzkirchen, March 06, 2012

Nine weeks before the expiration of the patent, HEXAL is launching Atorvastatin HEXAL® into the market.

Sandoz introduces authorized generic version of Clobex® Shampoo, 0.05%

Princeton, New Jersey, January 03, 2012

Sandoz today announced the introduction of clobetasol propionate shampoo, 0.05%, an authorized generic version of Clobex® Shampoo, 0.05%, in the US.

Sandoz launches voriconazole tablets, a generic version of Vfend®

Princeton, New Jersey, December 20, 2011

Sandoz today announced the US Food and Drug Administration (FDA) approval and US launch of voriconazole tablets, a generic equivalent of Vfend®.

Lek among the top 10

Ljubljana, November 25, 2011

Systematic investments in employee education and training

Lek among the most reputable employers in Slovenia

Ljubljana, November 24, 2011

As a part of the annual career fair Moje Delo 2011, the awards for the most reputable Slovenian companies, a survey conducted by the recruitment portal MojeDelo.com (MyJob.com), named Lek, a Sandoz company, one of the most reputable employers in Slovenia.

Sandoz Group Sends Strong Signal to Discount Contract Market

Holzkirchen, November 23, 2011

Clearly ahead in AOK call for tender

Sandoz Group continues to lead German generics market in Q3 2011

Holzkirchen, November 08, 2011

An analysis of most recent IMS figures show that the Sandoz Group, including HEXAL, Sandoz Pharmaceuticals, 1 A Pharma and Neocorp, continues to spearhead the German generics market at the end of Q3 2011.

Fit For Future 2011

October 19, 2011

Sandoz Austria Wins National Award: Best Apprenticing Company

Sandoz expands differentiated portfolio in US to include Alcon’s Falcon generic

Princeton, NJ, October 18, 2011

Sandoz announced today that effective this month it will be broadening its US portfolio with the ophthalmic and otic products of Falcon Pharmaceuticals, Ltd., Alcon’s US generics business. These Falcon products will now be marketed, sold and supported exclusively through Sandoz as part of the company’s diverse portfolio of high-quality generic products.

Sandoz expands US respiratory franchise with launches of Albuterol Sulfate and Ipratropium Bromide

Princeton, New Jersey, September 13, 2011

Sandoz today announced the US launches of albuterol sulfate inhalation solution, 0.083% and ipratropium bromide inhalation solution, 0.02% for the treatment of various respiratory diseases.

Sandoz expands Omnitrope® offering with FDA approval for a sixth indication

Princeton, New Jersey, September 01, 2011

Sandoz announced today that the US Food and Drug Administration (FDA) has approved its human growth hormone Omnitrope® (somatropin [rDNA origin] for injection) for a sixth indication, the treatment of children with growth failure due to Turner syndrome.

Sandoz continues to build oncology injectables portfolio with US launch of docetaxel injection, a ready-to-use version of Taxotere®

Princeton, New Jersey, August 23, 2011

Sandoz today announced US Food and Drug Administration (FDA) approval and the US launch of docetaxel injection, a ready-to-use version of Taxotere® injection concentrate.

Sandoz launches Letrozole, the generic version of Novartis’ Femara®

Frimley, UK, July 25, 2011

Sandoz Ltd. today announced the UK launch of Sandoz Letrozole, the generic version of Novartis’ Femara®, a drug used in the treatment of breast cancer.

Sandoz announces generic pharmaceuticals strategic alliance with Nipro Corporation in Japan

Tokyo,Japan, July 11, 2011

Sandoz today announced that it has entered into a strategic alliance with Nipro Corporation, which will focus on a broad range of cross-licensing and co-development opportunities for the Japanese generics market.

Sandoz launches generic versions of Levaquin® Tablets and Levaquin® Injection

Princeton, New Jersey, July 08, 2011

Sandoz today announced the US Food and Drug Administration (FDA) approval and US launch of levofloxacin tablets and levofloxacin in 5% dextrose injection.

Sandoz launches Syeda™, a generic version of Yasmin®

Princeton, New Jersey, June 08, 2011

Sandoz today announced the US Food and Drug Administration (FDA) approval and US launch of Syeda™ (drospirenone 3 mg /ethinyl estradiol 0.03 mg tablets), a generic equivalent of Yasmin®.

Sandoz launches donepezil HCL tablets, a generic version of Aricept®

Princeton, New Jersey, June 01, 2011

Sandoz today announced the US Food and Drug Administration (FDA) approval and US launch of donepezil hydrochloride (HCL) film-coated tablets and donepezil HCL orally-disintegrating tablets (ODT). Donepezil HCL film-coated tablets and donepezil HCL ODT are generic equivalents to Aricept® and Aricept® ODT, respectively.

First regional BioCamp in the Alpe-Adria region – excellent opportunity for top students to meet science and business

Ljubljana, May 30, 2011

From May 29 to 31, Lek, a Sandoz company, is hosting 35 select top undergraduate and graduate science students from the Alpe-Adria region, who will be meeting with distinguished experts and top managers from across Sandoz and Novartis.

Sandoz launches a new, ready-to-use formulation of argatroban injection (in Sodium Chloride)

Princeton, New Jersey, May 10, 2011

Sandoz today announced the US launch of argatroban injection (in sodium chloride), the first ready-to-use alternative to Pfizer’s concentrate formulation, following the US Food and Drug Administration (FDA) approval of the Sandoz New Drug Application.

Sandoz builds oral contraceptive portfolio with the launch of Loryna®, a generic version of YAZ®

Princeton, New Jersey, May 04, 2011

Sandoz today announced the US Food and Drug Administration (FDA) approval and US launch of its new oral contraceptive brand Loryna® (drospirenone 3 mg/ethinyl estradiol 0.02 mg tablets).

Sandoz launches Altavera®, a generic version of Nordette®

Princeton, New Jersey, April 08, 2011

Sandoz today announced the US Food and Drug Administration (FDA) approval and US launch of Altavera® (levonorgestrel and ethinyl estradiol tablets), a generic equivalent of Nordette®.

Sandoz ensures continued supply of levothyroxine sodium in Japan

Tokyo,Japan, April 01, 2011

Sandoz K.K. is pleased to announce that it has recently started importing levothyroxine sodium to meet the needs of Japanese patients, following the disruption of the product’s supply by the devastating effects of the natural disaster.

Sandoz launches meropenem for injection, USP, a generic version of Merrem® I.V.

Princeton, New Jersey, March 31, 2011

Sandoz today announced the introduction of meropenem for injection, USP, a generic equivalent of Merrem® I.V., in the US.

Sandoz introduces authorized generic version of Famvir®

Princeton, New Jersey, March 24, 2011

Sandoz today announced the introduction of famciclovir tablets, an authorized generic version of Famvir®, in the US. Famvir is currently marketed by Novartis Pharmaceuticals Corporation.

Sandoz launches imiquimod cream 5%, a generic version of Aldara®

Princeton, New Jersey, March 10, 2011

Sandoz today announced the US Food and Drug Administration (FDA) approval and US launch of imiquimod cream 5%. Imiquimod is a generic equivalent to Aldara®.

Sandoz launches Valsartan and Valsartan HCT, the generic versions of Diovan® and Diovan-HCT™

Montréal, QC, Canada, February 16, 2011

Sandoz today announced the launch of Sandoz* Valsartan and Sandoz* Valsartan-HCT, generic equivalents of Novartis’ Diovan® and Diovan-HCT™, in Canada.

Sandoz launches Introvale®, a generic version of Seasonale®

Princeton, New Jersey, January 05, 2011

Sandoz today announced the US Food and Drug Administration (FDA) approval and US launch of Introvale® (levonorgestrel and ethinyl estradiol tablets), a generic equivalent of Seasonale®.

Sandoz launches Sandoz Tamsulosin CR, the generic version of Flomax®CR

Montréal, QC, Canada, January 05, 2011

Sandoz today announced the launch of Tamsulosin CR, a generic equivalent to Flomax®CR from Boehringer Ingelheim, in Canada. Sandoz Tamsulosin CR (Controlled-Release Tablets) is a niche product indicated for the treatment of lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH).

Sandoz launches higher dosage strengths of authorized generic version of Lotrel®

Princeton, New Jersey, January 03, 2011

Sandoz today announced the introduction of two higher dosage strengths of amlodipine besylate/benazepril capsules, an authorized generic equivalent of Lotrel®, which is currently marketed by Novartis Pharmaceuticals Corporation.

Sandoz initiates voluntary recall in the US of all 50mg/2mL and 250mg/10mL vials of Methotrexate Injection, USP due to the presence of glass particulates

Princeton, New Jersey, October 27, 2010

Sandoz Inc. announced today it has initiated a voluntary recall in the US of all 50mg/2mL and 250mg/10mL vials of Sandoz and Parenta brand Methotrexate Injection, USP product (“methotrexate”) to the consumer/user level.

Sandoz announces launch of piperacillin and tazobactam for injection, a generic version of Zosyn®

Princeton, New Jersey, October 21, 2010

Sandoz today announced the launch of piperacillin and tazobactam for injection, a generic equivalent of Zosyn®, in the US.

Sandoz launches lansoprazole delayed-release orally disintegrating tablets (ODT), an authorized generic version of PREVACID® SoluTab

Princeton, New Jersey, October 19, 2010

Sandoz today announced the introduction of lansoprazole delayed-release orally disintegrating tablets (ODT), an authorized generic equivalent of Prevacid® SoluTab, in the US.

Sandoz receives FDA approval for another new indication for Omnitrope® and launches Patient Assistance Program

Princeton, New Jersey, August 30, 2010

Sandoz announced today that the US Food and Drug Administration (FDA) has approved its human growth hormone Omnitrope® (somatropin [rDNA origin] for injection) for another new indication, the treatment of Idiopathic Short Stature (ISS).

Sandoz opens new state-of-the-art development center in East Hanover, NJ

Princeton, NJ, June 28, 2010

Sandoz celebrated this week the formal launch of its new product development center located in East Hanover, New Jersey. The new development center will be a key site for Sandoz US development of generic medicines, with an emphasis on "first-to-file" applications with the FDA.

Lek first in Slovenia to offer generic rosuvastatin for lowering

Ljubljana, June 23, 2010

Lek, a Sandoz company, has developed rosuvastatin, a so-called superstatin from the most recent third generation statins, used for the treatment of high blood cholesterol. Slovenian patients will be among the first to benefit from this new generic medicine. All processes, from development to production of the final product and packaging, are the work of Lek associates.

Lek one of the strongest development centers in Slovenia

Ljubljana, June 15, 2010

At a visit to the Lek Development Center today, University of Ljubljana Chancellor Prof. Dr. Radovan Stanislav Pejovnik listened to proposed steps for promoting innovation and enhancing cooperation between the business and academic spheres. As one of Slovenia’s strongest development centers, Lek also presented these proposals at the May session of the Council for Science and Technology as starting points for the new National Research and Development (R&D) Program, in line with its desire to contribute to the country’s overall development.

Sandoz completes acquisition of Oriel Therapeutics, strengthening potential for global leadership in respiratory

Princeton, New Jersey, June 03, 2010

Sandoz announced today that it has completed its acquisition of Oriel Therapeutics, a privately held US pharmaceuticals company, for an undisclosed sum.

Sandoz launches generic version of Valtrex

Princeton, New Jersey, May 25, 2010

Sandoz today announced the introduction in the US of valacyclovir hydrochloride (HCl) tablets, a generic equivalent of Valtrex.

Sandoz launches Losartan potassium tablets

Princeton, New Jersey, April 08, 2010

Sandoz Inc. announced today the introduction in the US of losartan potassium and losartan potassium-hydrochlorothiazide (HCTZ) tablets, authorized generic equivalents of Merck's Cozaar® and Hyzaar®.

PAGE:   1 2 3 4 5 6 7 8 9